Edesa Biotech Revenue

Biotechnology Research • Markham, Ontario, Canada • 11-20 Employees

Edesa Biotech revenue & valuation

Annual revenue	$328,801
Revenue per employee	$17,000
Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues	$1,100,000
Total funding	$17,800,000

Key Contacts at Edesa Biotech

Nishani Rajakulendran

Director Of Clinical Operations

Leo Bonifacio

Director Of Business Development

Jenn Chao

Member, Board Of Directors, Edesa Biotech, Inc.

Company overview

Headquarters	100 Spy Court, Markham, ON L3R 5H6, CA
Phone number	+12898009600
Website	edesabiotech.com
NAICS	541714
SIC	873
Keywords	Biotechnology, Dermatology, Gastrointestinal, Vitiligo, Inflammatory, Autoimmune, Ards, Scleroderma, Covid, Contact Dermatitis, Systemic Sclerosis
Founded	2015
Employees	11-20
Socials

Edesa Biotech Email Formats

Edesa Biotech uses 2 email formats. The most common is {first initial}.{last name} (e.g., j.doe@edesabiotech.com), used 53.8% of the time.

Format	Example	Percentage
{first initial}.{last name}	j.doe@edesabiotech.com	53.8%
{first name}.{last name}	john.doe@edesabiotech.com	46.2%

About Edesa Biotech

Edesa Biotech, Inc. (Nasdaq: EDSA) is a clinical-stage biopharmaceutical company developing innovative ways to treat inflammatory and immune-related diseases. Our most advanced drug candidate is EB05 (paridiprubart), a monoclonal antibody developed for acute and chronic disease indications that involve dysregulated innate immune responses. Edesa is currently evaluating EB05 in a Phase 3 study as a potential treatment for Acute Respiratory Distress Syndrome (ARDS), a life-threatening form of respiratory failure. In addition, Edesa is developing an sPLA2 inhibitor, EB01, as a topical treatment for chronic Allergic Contact Dermatitis (ACD), a common occupational skin condition. The company has also received regulatory approval to conduct a Phase 2 trial its EB06 monoclonal antibody as a treatment for vitiligo, a life-altering autoimmune disease that causes skin to lose its color in patches. We also are planning a future Phase 2 study of paridiprubart for systemic sclerosis (scleroderma), an autoimmune rheumatic disorder that causes fibrosis (scarring/hardening) of skin and internal organs.

Employees by Management Level

Total employees: 11-20

Seniority

Employees

Entry

Director

Manager

Employees by Department

Edesa Biotech has 9 employees across 5 departments.

Departments

Number of employees

Funding Data

Explore Edesa Biotech's funding history, including investment rounds, total capital raised, and key backers.

Funding Date	Round	Amount	Link to Article
2023-11-12	16	$7,300,000
2025-03-13	14	$10,500,000

Funding Insights

$17,800,000

Total funding amount

$10,500,000

Most recent funding amount

Number of funding rounds

Edesa Biotech Tech Stack

Discover the technologies and tools that power Edesa Biotech's digital infrastructure, from frameworks to analytics platforms.

reCAPTCHA

Security

JavaScript graphics

jQuery Mobile

Mobile frameworks

lit-element

JavaScript libraries

Google Maps

Maps

lit-html

JavaScript libraries

jQuery Migrate

JavaScript libraries

Apache HTTP Server

Web servers

Twitter Ads

Advertising

jQuery

JavaScript libraries

PHP

Programming languages

HSTS

Security

Frequently asked questions

Edesa Biotech is located in Markham, Ontario, CA.

You can reach Edesa Biotech at +12898009600.

Edesa Biotech generates an estimated annual revenue of $328,801. This revenue figure reflects the company's market position and business performance in its industry.

Edesa Biotech has an estimated valuation of $1,100,000. This valuation is calculated based on industry-standard revenue multiples and reflects the company's growth potential and market positioning.

Edesa Biotech was founded in 2015, making it 11 years old. The company has established itself as a significant player in its industry over this time.

Edesa Biotech has approximately 11-20 employees. The company continues to grow its workforce to support its business operations and expansion.

Edesa Biotech has raised a total of $17,800,000 across 2 funding rounds. This investment has helped the company grow and expand its operations.

Key Contacts at Edesa Biotech

Nishani Rajakulendran

Director Of Clinical Operations

Leo Bonifacio

Director Of Business Development

Jenn Chao

Member, Board Of Directors, Edesa Biotech, Inc.

4.8

40,000 users